Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile …

Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergill…

Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection.[A235384,L34349] It was developed out of a nee…

Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as [caspofungin] and [micafungin], rezafungin has long?acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining hig…